Monoclonal Antibodies Used in Combination for HCC

Atezolizumab/Bevacizumab Benefit Potentially Extends to Child-Pugh B HCC

June 4th 2024

Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.

Atezolizumab/Bevacizumab Shows Survival and QOL Benefit in HCC

ByStacey Stein, MD

May 1st 2024

Stacey Stein, MD, discusses the background and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma.